iTeos Therapeutics Inc. (ITOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ITOS Stock Price Chart Interactive Chart >
ITOS Price/Volume Stats
|Current price||$20.03||52-week high||$47.61|
|Prev. close||$19.86||52-week low||$17.43|
|Day high||$20.19||Avg. volume||279,404|
|50-day MA||$23.47||Dividend yield||N/A|
|200-day MA||$28.76||Market Cap||703.13M|
iTeos Therapeutics Inc. (ITOS) Company Bio
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.
ITOS Latest News Stream
|Loading, please wait...|
ITOS Latest Social Stream
View Full ITOS Social Stream
Latest ITOS News From Around the Web
Below are the latest news stories about iTeos Therapeutics Inc that investors may wish to consider to help them evaluate ITOS as an investment opportunity.
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including previously reported confirmed partial responses in patients with checkpoint-inhibitor resistant melanoma and heavily pretreated castrate-resistant prostate cancer, and a newly reported patient with heavily pretreated non-small cell lung cancer who had stable disease lasting more than 10 months Prelimi
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:00 a.m. ET. A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical compa...
iTeos Therapeutics, Inc. (ITOS) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Ryan Baker – Head of Investor Relations Michel Detheux – President and Chief Executive Officer Joe Lager – Chief Medical Officer Matthew Gall – Chief Financial Officer Conference Call Participants Chris Raymond –...
iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of Tony Ho, M.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. They will expand the clinical drug development and strategy expertise of iTeos Board with their track record in leading pharma and biotech companies. “We are thrilled to welcome Tony and Robert to our board as we advance our highly innovative immuno-oncology pipeline programs through clinical development,” said David Hallal, Chairman of the Board of iTeos Therapeutics. “Tony and Robert bring ex...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ITOS Price Returns